AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34213819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin in E/SE Asian subjects
Number of subjects: 2276
Study 34213819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin in Asian subjects from mainland China
Number of subjects: 2276
Study 34213819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin in Asian subjects from the rest of the world
Number of subjects: 2276
Study 34213819 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-Asian subjects)
Number of subjects: 2276
Study 34213962 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine treatment for memory impairment after TBI
Number of subjects: 0
Study 34214012 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld Ultrasound
Number of subjects: 0
Study 34214012 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 34214495 — intervention group
Group type: EXPERIMENTAL
Intervention: NSC-CRAd-S-pk7
Number of subjects: 12
Study 34214647 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation Testing (DT+)
Number of subjects: 566
Study 34214647 — intervention group
Group type: COMPARATOR
Intervention: No Defibrillation Testing (DT-)
Number of subjects: 566
Study 34215024 — intervention group
Group type: EXPERIMENTAL
Intervention: NTLA-2001 (0.1 mg/kg)
Number of subjects: 6
Study 34215024 — intervention group
Group type: EXPERIMENTAL
Intervention: NTLA-2001 (0.3 mg/kg)
Number of subjects: 6
Study 34215176 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM+MI
Number of subjects: 70
Study 34215176 — intervention group
Group type: COMPARATOR
Intervention: PAM
Number of subjects: 70
Study 34215288 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home lactation support intervention provided by International Board Certified Lactation Consultants (IBCLCs) during postpartum home visits.
Number of subjects: 210
Study 34215288 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home lactation support intervention
Number of subjects: 210
Study 34215307 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding initiation and duration
Number of subjects: 29953
Study 34215307 — intervention group
Group type: EXPERIMENTAL
Intervention: Total breastfeeding duration
Number of subjects: 29953
Study 34215307 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding duration
Number of subjects: 29953
Study 34215307 — intervention group
Group type: EXPERIMENTAL
Intervention: Support perception during breastfeeding
Number of subjects: 29953
Study 34215307 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire to breastfeed longer than two months
Number of subjects: 29953
Study 34215307 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for not breastfeeding
Number of subjects: 29953
Study 34215317 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model development using logistic regression with predictors including residual depressive symptoms, number of previous depressive episodes, co-morbid anxiety, and severity of index episode.
Number of subjects: 0
Study 34215317 — intervention group
Group type: EXPERIMENTAL
Intervention: Full model development approach including all available predictors.
Number of subjects: 0
Study 34215317 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal-external cross-validation for generalisability assessment.
Number of subjects: 0
Study 34215317 — intervention group
Group type: EXPERIMENTAL
Intervention: Net benefit analysis for clinical utility exploration.
Number of subjects: 0
Study 34215319 — intervention group
Group type: EXPERIMENTAL
Intervention: SB cell treatment (1 × 10)
Number of subjects: 9
Study 34215319 — intervention group
Group type: EXPERIMENTAL
Intervention: SB cell treatment
Number of subjects: 9
Study 34215323 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment for conduct disorder (MBT-CD)
Number of subjects: 100
Study 34215600 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision rule for identifying older adults at risk of clinically important intracranial bleeding after a fall.
Number of subjects: 0
Study 34215614 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyfe Cough Tracker app for monitoring night-time cough
Number of subjects: 0
Study 34215684 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary daily noise monitoring intervention
Number of subjects: 110
Study 34215684 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched for job title, age, gender, race, plant location, and baseline hearing level)
Number of subjects: 110
Study 34215909 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa treatment
Number of subjects: 21
Study 34216069 — intervention group
Group type: COMPARATOR
Intervention: CRT-D therapy
Number of subjects: 2618
Study 34216069 — intervention group
Group type: COMPARATOR
Intervention: ICD implant
Number of subjects: 2618
Study 34216189 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL apheresis (LDL-A) for 4 weeks, 6 sessions
Number of subjects: 34
Study 34216189 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy with corticosteroids and statins
Number of subjects: 34
Study 34216197 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-BANG (≥ 3)
Number of subjects: 48
Study 34216197 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-BANG (≥ 5)
Number of subjects: 48
Study 34216197 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-item analyses in OSA-positive subsample
Number of subjects: 48
Study 34216221 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan findings in AII patients
Number of subjects: 48
Study 34216247 — intervention group
Group type: EXPERIMENTAL
Intervention: Budigalimab 250 mg intravenously Q2W
Number of subjects: 81
Study 34216247 — intervention group
Group type: EXPERIMENTAL
Intervention: Budigalimab 500 mg intravenously Q4W
Number of subjects: 81
Study 34216247 — intervention group
Group type: EXPERIMENTAL
Intervention: Budigalimab (both dosing regimens)
Number of subjects: 81
Study 34216598 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-scale artificial intelligence system for polyp detection during colonoscopy
Number of subjects: 0
Study 34216598 — intervention group
Group type: COMPARATOR
Intervention: Traditional colonoscopy without AI assistance
Number of subjects: 0
Study 34216757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2524
Study 34216825 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support tool for infliximab
Number of subjects: 0
Study 34216825 — intervention group
Group type: COMPARATOR
Intervention: Vedolizumab
Number of subjects: 0
Study 34216825 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 0
Study 34217109 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel effective therapies targeting key signaling pathways in PAH
Number of subjects: 0
Study 34217304 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTIMAT™-intervention (4-week lunch menu)
Number of subjects: 42
Study 34217326 — intervention group
Group type: EXPERIMENTAL
Intervention: BREAST-Q LD questionnaire (appearance subscale)
Number of subjects: 125
Study 34217326 — intervention group
Group type: EXPERIMENTAL
Intervention: BREAST-Q LD questionnaire (function subscale)
Number of subjects: 125
Study 34217326 — intervention group
Group type: EXPERIMENTAL
Intervention: BREAST-Q LD questionnaire (both subscales)
Number of subjects: 125
Study 34217326 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability (ICCs)
Number of subjects: 125
Study 34217326 — intervention group
Group type: COMPARATOR
Intervention: Known-group validation (patients vs normal controls)
Number of subjects: 125
Study 34217404 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 2007
Study 34217404 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical-banded gastroplasty
Number of subjects: 2007
Study 34217404 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric banding
Number of subjects: 2007
Study 34217404 — intervention group
Group type: COMPARATOR
Intervention: Usual obesity care (Control)
Number of subjects: 2007
Study 34217426 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral PrEP (coformulated tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg)
Number of subjects: 9709
Study 34217773 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide
Number of subjects: 214
Study 34217841 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple nerve blocks (MNB)
Number of subjects: 593
Study 34217841 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous spinal anaesthesia (CSA)
Number of subjects: 593
Study 34217841 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 593
Study 34217888 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified protocol (n=37)
Number of subjects: 69
Study 34217888 — intervention group
Group type: COMPARATOR
Intervention: Original protocol (n=32)
Number of subjects: 69
Study 34217908 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib, pembrolizumab, and letrozole
Number of subjects: 23
Study 34218284 — intervention group
Group type: EXPERIMENTAL
Intervention: S antibodies
Number of subjects: 3679
Study 34218284 — intervention group
Group type: EXPERIMENTAL
Intervention: N antibodies
Number of subjects: 3679
Study 34218680 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary blood samples (first and second drops) taken after wiping the finger with alcohol
Number of subjects: 109
Study 34218680 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary blood samples (first and second drops) taken 2 hours after OGTT
Number of subjects: 109
Study 34218718 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Magnetic Stimulation
Number of subjects: 0
Study 34218718 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34218972 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging diagnostics (both commercial and academic)
Number of subjects: 0
Study 34219224 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 536
Study 34219224 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum
Number of subjects: 536
Study 34219224 — intervention group
Group type: EXPERIMENTAL
Intervention: Synsorb Pk (Shiga toxin binding agent)
Number of subjects: 536
Study 34219224 — intervention group
Group type: EXPERIMENTAL
Intervention: Urtoxazumab (3.0 mg/kg)
Number of subjects: 536
Study 34219224 — intervention group
Group type: EXPERIMENTAL
Intervention: Urtoxazumab (1.0 mg/kg)
Number of subjects: 536
Study 34219224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study 34219653 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD-TDV dengue vaccine
Number of subjects: 0
Study 34219663 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon pulmonary angioplasty (BPA)
Number of subjects: 236
Study 34220581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride (0.5 mg/kg)
Number of subjects: 34
Study 34220581 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 34
Study 34221918 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Number of subjects: 334
Study 34221918 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 334
Study 34221987 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-gene Oncotype DX Breast DCIS Score
Number of subjects: 104
Study 34221987 — intervention group
Group type: COMPARATOR
Intervention: Whole breast radiotherapy
Number of subjects: 104
Study 34222013 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine with a modified DHAP regimen
Number of subjects: 21
Study 34222272 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34222294 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting 90-day survival
Number of subjects: 0
Study 34222308 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich intervention
Number of subjects: 0
Study 34222308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34222435 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingzhong (Tenofovir disoproxil fumarate)
Number of subjects: 330
Study 34222435 — intervention group
Group type: EXPERIMENTAL
Intervention: Viread (Tenofovir disoproxil fumarate)
Number of subjects: 330
Study 34222719 — intervention group
Group type: EXPERIMENTAL
Intervention: IONIS-AGT-L
Number of subjects: 0
Study 34222719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34222761 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection and use for decision making
Number of subjects: 0
Study 34222761 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration between health department officials
Number of subjects: 0
Study 34222761 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly review meetings with staff and supervisors
Number of subjects: 0
Study 34222761 — intervention group
Group type: EXPERIMENTAL
Intervention: Human resource gaps, inadequate technology infrastructure, FLW educational level, political structure, and lack of cooperation between FLWs and supervisors
Number of subjects: 0
Study 34222765 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging and Facebook groups
Number of subjects: 450
Study 34222765 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook content
Number of subjects: 450
Study 34222765 — intervention group
Group type: EXPERIMENTAL
Intervention: HCSF2 Facebook groups
Number of subjects: 450
Study 34222765 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement levels
Number of subjects: 450
Study 34222848 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC-COV1901 5 μg
Number of subjects: 45
Study 34222848 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC-COV1901 15 μg
Number of subjects: 45
Study 34222848 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC-COV1901 25 μg
Number of subjects: 45
Study 34222848 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC-COV1901
Number of subjects: 45
Study 34222849 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate and emtricitabine (2 pills on day 1 followed by 1 pill per day on days 2-7)
Number of subjects: 0
Study 34222849 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 34222847 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (NTZ) 600 mg BID for seven days
Number of subjects: 50
Study 34222847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 34222847 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (NTZ)
Number of subjects: 50
Study 34223253 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified human menotropin (HP-hMG)
Number of subjects: 619
Study 34223253 — intervention group
Group type: COMPARATOR
Intervention: Recombinant follicle-stimulating hormone (FSH)
Number of subjects: 619
Study 34223253 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-hMG
Number of subjects: 619
Study 34223253 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 619
Study 34223342 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical activity among OHCA-survivors
Number of subjects: 220
Study 34223342 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective measure of physical activity using a hip-placed accelerometer
Number of subjects: 220
Study 34223342 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessments of anxiety symptoms, depression symptoms, kinesiophobia, and fatigue
Number of subjects: 220
Study 34223342 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical activity questions after one week of accelerometer use
Number of subjects: 220
Study 34223342 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments at 6 months after OHCA
Number of subjects: 220
Study 34223342 — intervention group
Group type: COMPARATOR
Intervention: Follow-up meeting for MI-controls
Number of subjects: 220
Study 34223347 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin and Methylprednisolone (40 mg methylprednisolone and 20 IU vasopressin, with additional doses of vasopressin after each adrenaline dose for a maximum of four doses)
Number of subjects: 492
Study 34223347 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 492
Study 34223356 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV-Refresher program (psychomotor skill training using a newborn manikin with visual feedback)
Number of subjects: 26
Study 34223356 — intervention group
Group type: COMPARATOR
Intervention: Baseline assessment
Number of subjects: 26
Study 34223388 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care naloxone distribution
Number of subjects: 30
Study 34223388 — intervention group
Group type: COMPARATOR
Intervention: Referral to an existing program
Number of subjects: 30
Study 34223403 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose metabolism via glycolysis
Number of subjects: 0
Study 34223403 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidative pentose phosphate pathway (oxPPP)
Number of subjects: 0
Study 34223403 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose feeding amino acid synthesis
Number of subjects: 0
Study 34223403 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolysis
Number of subjects: 0
Study 34223403 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate exchange via monocarboxylic transporters
Number of subjects: 0
Study 34223403 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose metabolism
Number of subjects: 0
Study 34223402 — intervention group
Group type: EXPERIMENTAL
Intervention: RH5.1 recombinant protein vaccine
Number of subjects: 0
Study 34223402 — intervention group
Group type: EXPERIMENTAL
Intervention: RH5.1/AS01
Number of subjects: 0
Study 34223516 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation practices
Number of subjects: 0
Study 34223895 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin (recombinant leptin)
Number of subjects: 38
Study 34224257 — intervention group
Group type: EXPERIMENTAL
Intervention: Surge index (severity-weighted measure of COVID-19 caseload)
Number of subjects: 144116
Study 34224257 — intervention group
Group type: EXPERIMENTAL
Intervention: Surge index
Number of subjects: 144116
Study 34224261 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion Centers (ICs)
Number of subjects: 269
Study 34224261 — intervention group
Group type: COMPARATOR
Intervention: Emergency Departments (EDs)
Number of subjects: 269
Study 34224302 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop ileostomy closure in a 23-h stay setting
Number of subjects: 30
Study 34224302 — intervention group
Group type: COMPARATOR
Intervention: Standard in-hospital stoma closure (historical control)
Number of subjects: 30
Study 34224432 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon pulmonary angioplasty (BPA)
Number of subjects: 0
Study 34224432 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with BPA
Number of subjects: 0
Study 34224432 — intervention group
Group type: EXPERIMENTAL
Intervention: BPA alone or in combination with PEA or medical therapy
Number of subjects: 0
Study 34224438 — intervention group
Group type: EXPERIMENTAL
Intervention: Stored slides
Number of subjects: 21
Study 34224438 — intervention group
Group type: COMPARATOR
Intervention: Freshly cut slides
Number of subjects: 21
Study 34224466 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with anxiety symptoms
Number of subjects: 12913
Study 34224466 — intervention group
Group type: COMPARATOR
Intervention: Patients without anxiety symptoms
Number of subjects: 12913
Study 34224466 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without anxiety)
Number of subjects: 12913
Study 34224497 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia (FM) patients
Number of subjects: 57
Study 34224497 — intervention group
Group type: COMPARATOR
Intervention: Rheumatoid arthritis (RA) patients
Number of subjects: 57
Study 34224500 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ simulation training
Number of subjects: 15
Study 34224572 — intervention group
Group type: EXPERIMENTAL
Intervention: FODMAP intake
Number of subjects: 109362
Study 34224572 — intervention group
Group type: EXPERIMENTAL
Intervention: Total FODMAPs
Number of subjects: 109362
Study 34224572 — intervention group
Group type: EXPERIMENTAL
Intervention: FODMAP consumption
Number of subjects: 109362
Study 34224583 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 1906
Study 34224668 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (2 doses)
Number of subjects: 885
Study 34224674 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation
Number of subjects: 1909
Study 34224684 — intervention group
Group type: EXPERIMENTAL
Intervention: XC001 gene therapy
Number of subjects: 33
Study 34225165 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stress
Number of subjects: 169
Study 34225165 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional eating (mediating variable)
Number of subjects: 169
Study 34225165 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stress controlling for emotional eating
Number of subjects: 169
Study 34225229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 1076
Study 34225348 — intervention group
Group type: EXPERIMENTAL
Intervention: LTOWB + CT
Number of subjects: 70
Study 34225348 — intervention group
Group type: COMPARATOR
Intervention: CT only
Number of subjects: 70
Study 34225496 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 710
Study 34225735 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Rehabilitation with autonomy recovery and multimodal exercise programmes
Number of subjects: 50
Study 34225735 — intervention group
Group type: COMPARATOR
Intervention: Multimodal exercise programme
Number of subjects: 50
Study 34225764 — intervention group
Group type: EXPERIMENTAL
Intervention: SENSory re-learning of the UPPer limb after stroke (SENSUPP)
Number of subjects: 0
Study 34225817 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated Specialty Care (CSC) services modifications during and after the COVID-19 crisis
Number of subjects: 0
Study 34225817 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with multi-level stakeholders
Number of subjects: 0